Capivasertib (C) plus paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial

被引：0

作者：

Schmid, P. ^{[1
]}

McArthur, H. L. ^{[2
]}

Cortes, J. ^{[3
,4
]}

Xu, B. ^{[5
]}

Cardoso, F. ^{[6
]}

Casalnuovo, M. L. ^{[7
]}

Demirci, U. ^{[8
]}

Freitas, R., Jr. ^{[9
]}

Ghosh, J. ^{[10
]}

Hegg, R. ^{[11
]}

Iwata, H. ^{[12
]}

Chuken, Y. A. Lopez ^{[13
]}

Nechaeva, M. ^{[14
]}

Robson, M. E. ^{[15
]}

Villalobos Valencia, R. ^{[16
]}

Lloyd, A. ^{[17
]}

D'Cruz, C. ^{[18
]}

Foxley, A. ^{[18
]}

Park, Y. H. ^{[19
]}

机构：

[1] Queen Mary Univ, Barts Canc Inst, Ctr Expt Canc Med, London, England

[2] UT Southwestern Med Ctr, Dallas, TX USA

[3] IBCC, Pangaea Grp, Barcelona, Spain

[4] IOB Madrid, Inst Oncol, Barcelona, Spain

[5] Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China

[6] Champalimaud Fdn, Champalimaud Clin Ctr, Breast Unit, Lisbon, Portugal

[7] CENIT Ctr Med Neurociencias, Buenos Aires, DF, Argentina

[8] Mem Ankara Hosp, Ankara, Turkiye

[9] Hosp Araujo Jorge, Goiania, Go, Brazil

[10] Tata Med Ctr, Kolkata, India

[11] Sao Paulo State Govt Womens Hlth Reference Ctr, Sao Paulo, Brazil

[12] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[13] ICAN Oncol Ctr, Monterrey, Mexico

[14] Arkhangelsk Reg Clin Oncol Dispensary, Arkhangelsk, Russia

[15] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[16] Consultorio Ctr Torre Med Dalinde, Oncol Med, Mexico City, DF, Mexico

[17] AstraZeneca, Oncol R&D, Cambridge, England

[18] AstraZeneca, Oncol R&D, Waltham, MA USA

[19] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.2257

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA19

引用

页码：1212 / 1213

页数：2

共 50 条

[31] Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
Kim, Sung-Bae
Dent, Rebecca
Im, Seock-Ah
Espie, Marc
Blau, Sibel
Tan, Antoinette R.
Isakoff, Steven J.
Oliveira, Mafalda
Saura, Cristina
Wongchenko, Matthew J.
Kapp, Amy V.
Chan, Wai Y.
Singel, Stina M.
Maslyar, Daniel J.
Baselga, Jose
LANCET ONCOLOGY, 2017, 18 (10): : 1360 - 1372
[32] COST-EFFECTIVENESS OF PEMBROLIZUMAB PLUS CHEMOTHERAPIES FOR FIRST-LINE TREATMENT IN LOCALLY ADVANCED UNRESECTABLE OR METASTATIC TRIPLE NEGATIVE BREAST CANCER (MTNBC) IN FRANCE
Tredan, O.
Bensimon, L.
Apert, M.
Tehard, B.
Carita, M.
Khandelwal, A.
Gandhi, J.
Haiderali, A.
Huang, M.
Levy, P.
VALUE IN HEALTH, 2022, 25 (12) : S54 - S55
[33] Patterns and predictors of first-line (1L) taxane use in US patients with metastatic triple-negative breast cancer (mTNBC)
O'Shaughnessy, J.
Emens, L. A.
Chui, S.
Russell, K.
Lin, S. -W.
Avile, C. Flores
Luhn, P.
Schneeweiss, A.
ANNALS OF ONCOLOGY, 2019, 30 : 131 - 131
[34] The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype
Kenjiro Aogi
Masayuki Yoshida
Yoshiaki Sagara
Shunji Kamigaki
Minoru Okazaki
Jumpei Funai
Toshio Fujimoto
Masakazu Toi
Toshiaki Saeki
Shigemitsu Takashima
Cancer Chemotherapy and Pharmacology, 2011, 67 : 1007 - 1015
[35] The efficacy and safety of gemcitabine plus paclitaxel combination first-line therapy for Japanese patients with metastatic breast cancer including triple-negative phenotype
Aogi, Kenjiro
Yoshida, Masayuki
Sagara, Yoshiaki
Kamigaki, Shunji
Okazaki, Minoru
Funai, Jumpei
Fujimoto, Toshio
Toi, Masakazu
Saeki, Toshiaki
Takashima, Shigemitsu
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 67 (05) : 1007 - 1015
[36] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
Lueck, Hans-Joachim
Du Bois, Andreas
Loibl, Sibylle
Schrader, Iris
Huober, Jens
Heilmann, Volker
Beckmann, Matthias
Staehler, Ann
Jackisch, Christian
Hubalek, Michael
Richter, Barbara
Stickeler, Elmar
Eidtmann, Holger
Thomssen, Christoph
Untch, Michael
Wollschlaeger, Kerstin
Schuster, Tibor
von Minckwitz, Gunter
BREAST CANCER RESEARCH AND TREATMENT, 2013, 139 (03) : 779 - 787
[37] Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group
Hans-Joachim Lück
Andreas Du Bois
Sibylle Loibl
Iris Schrader
Jens Huober
Volker Heilmann
Matthias Beckmann
Ann Stähler
Christian Jackisch
Michael Hubalek
Barbara Richter
Elmar Stickeler
Holger Eidtmann
Christoph Thomssen
Michael Untch
Kerstin Wollschläger
Tibor Schuster
Gunter von Minckwitz
Breast Cancer Research and Treatment, 2013, 139 : 779 - 787
[38] First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer A Cost-Effectiveness Analysis
Weng, Xiuhua
Huang, Xiaoting
Li, Hongchao
Lin, Shen
Rao, Xin
Guo, Xianzhong
Huang, Pinfang
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2020, 43 (05): : 340 - 348
[39] WHETHER CHIDAMIDE IMPROVES THE RESPONSE TO CISPLATIN IN FIRST-LINE TREATMENT OF METASTATIC TRIPLE-NEGATIVE BREAST CANCER
Zhang, Jian
Hu, Xichun
Meng, Yanchun
Jin, Juan
Gong, Chengcheng
Miao, Haitao
Tao, Zhonghua
Li, Ting
Cao, Jun
Wang, Leiping
Wang, Biyun
Hu, Xichun
BREAST, 2021, 59 : S46 - S46
[40] Updated survival data and biomarker assessment of the CBCSG006 trial: A randomized phase III trial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer.
Zhang, Jian
Lin, Ying
Hu, Xi-Chun
Yang, Wentao
Sun, Xiangjie
Wang, Biyun
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

← 1 2 3 4 5 →